NCT04121286 is a Phase 1 clinical trial of JAB-3312 in Non-small Cell Lung Cancer, sponsored by Allist Pharmaceuticals, Inc..

Who is sponsoring NCT04121286?

NCT04121286 is sponsored by Allist Pharmaceuticals, Inc..

What drugs are being tested in NCT04121286?

Interventions in NCT04121286: JAB-3312.

What condition does NCT04121286 study?

NCT04121286 studies Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors.

Is NCT04121286 still recruiting?

NCT04121286 is currently completed. Last updated 20 May 2025.

Last reviewed 2025-05-20 · How we verify

NCT04121286

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China

Completed Phase 1 Last updated 20 May 2025

What this trial tests

Phase 1 trial testing JAB-3312 in Non-small Cell Lung Cancer in 17 participants. Completed in 17 June 2022.

Timeline

14 July 2020

Primary endpoint
17 June 2022

17 June 2022

Quick facts

Lead sponsor	Allist Pharmaceuticals, Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	17
Start date	14 July 2020
Primary completion	17 June 2022
Estimated completion	17 June 2022
Sites	5 locations across China

Drugs / interventions tested

JAB-3312 — full drug profile →

Conditions studied

Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
Colorectal Cancer — all drugs for Colorectal Cancer →
Pancreatic Ductal Carcinoma — all drugs for Pancreatic Ductal Carcinoma →
Esophageal Squamous Cell Carcinoma — all drugs for Esophageal Squamous Cell Carcinoma →

Sponsor

Allist Pharmaceuticals, Inc. — full company profile →

Who can join

18 and older, any sex, with Non-small Cell Lung Cancer or Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-3312 will be administered orally once daily (QD) in 21-day treatment cycles.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

The current state of the art and future trends in RAS-targeted cancer therapies.
Punekar SR, Velcheti V, Neel BG, Wong KK. · · 2022 · cited 382× · PMID 36028717 · DOI 10.1038/s41571-022-00671-9
Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.
Xie X, Yu T, Li X, Zhang N, et al · · 2023 · cited 246× · PMID 37669923 · DOI 10.1038/s41392-023-01589-z
Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.
Hu HF, Ye Z, Qin Y, Xu XW, et al · · 2021 · cited 116× · PMID 33574569 · DOI 10.1038/s41401-020-00584-2
Targeting <i>KRAS</i> Mutant Non-Small-Cell Lung Cancer: Past, Present and Future.
Uras IZ, Moll HP, Casanova E. · · 2020 · cited 109× · PMID 32560574 · DOI 10.3390/ijms21124325
Mechanisms of Resistance to KRAS<sup>G12C</sup> Inhibitors.
Dunnett-Kane V, Nicola P, Blackhall F, Lindsay C. · · 2021 · cited 90× · PMID 33466360 · DOI 10.3390/cancers13010151
Targeting protein phosphatases for the treatment of inflammation-related diseases: From signaling to therapy.
Pan J, Zhou L, Zhang C, Xu Q, et al · · 2022 · cited 83× · PMID 35665742 · DOI 10.1038/s41392-022-01038-3
Targeting KRAS in pancreatic cancer: new drugs on the horizon.
Bannoura SF, Uddin MH, Nagasaka M, Fazili F, et al · · 2021 · cited 81× · PMID 34499267 · DOI 10.1007/s10555-021-09990-2
Targeting protein phosphatases in cancer immunotherapy and autoimmune disorders.
Stanford SM, Bottini N. · · 2023 · cited 80× · PMID 36693907 · DOI 10.1038/s41573-022-00618-w

Verify or expand the search:

Other trials of JAB-3312

Trials testing the same drug.

NCT06416410 — JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT04720976 — JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors · Phase 1, PHASE2 · completed
NCT04045496 — A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors · Phase 1 · completed

Other recruiting trials for Non-small Cell Lung Cancer

Currently open trials in the same condition.

NCT07431827 — MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013) · Phase 3 · recruiting
NCT05987956 — Pharmacogenomics IND EXEMPT SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms · Phase 2, PHASE3 · active not recruiting
NCT07195695 — Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06686771 — Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer · Phase 3 · recruiting
NCT06477055 — The Recurrence Gene Profiles of Adjuvant Osimertinib Therapy in Resected Non-Small-Cell Lung Cancer · recruiting

Other Allist Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT07010419 — A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With St · Phase 3 · recruiting
NCT06416410 — JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer Wit · Phase 3 · recruiting
NCT06162169 — A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects · Phase 1 · completed
NCT06008288 — A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harbor · Phase 2 · recruiting
NCT05920941 — Mass Balance Study of [14C]JAB-21822 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04121286 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Allist Pharmaceuticals, Inc.
Last refreshed: 20 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04121286.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing